Simcere Announces Appointment of Mr. Zhou Gaobo as Chief Investment Officer
Trilaciclib Received Priority Review from NMPA! Patient Enrolment Achieved for Three Indications in Phase III Study in China
Simcere Announced CTA Approval for SCR6852, an investigational SERD molecule that can Cross Blood-brain-barrier for breast cancer treatment
FDA Fast Track Designation granted for Varoglutamstat in Early Alzheimer’s disease
Simcere and Avilex Pharma Announce Strategic Regional Licensing Partnership to Develop and Commercialize AVLX-144 for the Treatment of Acute Ischemic Stroke (AIS) in Greater China
The Clinical Trial Application of Alzheimer's Disease Drug Varoglutamstat Accepted for Review by China CDE
Simcere Project X, only for “daring explorers”!
Aeromics and Simcere Announce the First-In-Human Dosing of Chinese Healthy Volunteers in Simcere's Phase I Study of The SIM0307 (AER-271), A New Drug for Brain Edema
Envafolimab, The World’s First Subcutaneously Injected PD-L1 Antibody Approved by NMPA! Simcere Partners with Alphamab Oncology and 3DMed to Innovate Immunotherapy
Simcere and Shanghai Institute of Materia Medica Enter a Collaboration to Jointly Develop Next-Gen COVID-19 Oral Antiviral Treatments